Skip to Main Content
header search
Search
Skip Nav Destination

Issues

Volume 5, Issue 6
1 November 2015
Issue Cover
eISSN 2168-9709

Off-Label Medications: Evidence-Based Use, Vol. 5, Iss. 6

CLINICAL PEARL

Off-label use of gabapentin for management of alcohol use disorders
Taylor A. Nichols, PharmD
View Articletitled, Off-label use of gabapentin for management of alcohol use disorders
Open the PDF for in another window

LITERATURE REVIEWS

Triiodothyronine (T3) supplementation in major depressive disorder
Anna K. Morin, PharmD
View Articletitled, Triiodothyronine (T3) supplementation in major depressive disorder
Open the PDF for in another window
Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors for menopausal vasomotor symptoms
Kathryn M. Holt, PharmD; Amy N. Thompson, PharmD, BCACP, CDE
View Articletitled, Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors for menopausal vasomotor symptoms
Open the PDF for in another window
Off-label use of mirtazapine for anxiety
John Begert, PharmD; Bridget Bradley, PharmD, BCPP
View Articletitled, Off-label use of mirtazapine for anxiety
Open the PDF for in another window
The role of methylphenidate in depression
Meghan Ellinger May, PharmD; Amy VandenBerg, PharmD, BCPP
View Articletitled, The role of methylphenidate in depression
Open the PDF for in another window

Case Report

Off-label use of duloxetine for pediatric neuropathic pain
K. J. Burghardt, PharmD; S. T. Thomas, MD; V. Tutag-Lehr, PharmD
View Articletitled, Off-label use of duloxetine for pediatric neuropathic pain
Open the PDF for in another window

REVIEW OF DRUGS/PHARMACOTHERAPY

Pharmacologic basis for the use of selective norepinephrine reuptake inhibitors for the treatment of neuropathic pain conditions
Michael Webster, PharmD
View Articletitled, Pharmacologic basis for the use of selective norepinephrine reuptake inhibitors for the treatment of neuropathic pain conditions
Open the PDF for in another window
Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors for the treatment of painful neuropathy
Meredith Sigler, PharmD, BCPS; Amy VandenBerg, PharmD, BCPP; Amy Thompson, PharmD, BCACP, CDE
View Articletitled, Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors for the treatment of painful neuropathy
Open the PDF for in another window
All Issues
  • eISSN 2168-9709
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept